Abstract

253P Is 6-weekly administration of pembrolizumab in combination with chemotherapy for early triple-negative breast cancer safe? A real-world early comparison of q6w versus q3w administration of pembrolizumab in two large cancer centres in the UK

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
The Role of Ultrasound of the Regional Nodal Basins in Staging Patients With Triple-Negative Breast Cancer: Implications for Local-Regional Treatment
S.F Shaitelman ... G.J Whitman
International Journal of Radiation Oncology, Biology, Physics | VOL. 90
S.F Shaitelman, et. al.S.F Shaitelman ... G.J Whitman
01 Sep 2014
Abstract P3-03-01: The impact of the COVID19 pandemic on treatment practices for patients diagnosed with early breast cancer: a cross-sectional study from a large comprehensive cancer centre in Italy
Fabio Girardi ... Tania Saibene
American Journal of Cancer | VOL. 83
Fabio Girardi, et. al.Fabio Girardi ... Tania Saibene
01 Mar 2023
Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancer
Maximilian Marhold ... Rupert Bartsch
OncoImmunology | VOL. 12
Maximilian Marhold, et. al.Maximilian Marhold ... Rupert Bartsch
13 Nov 2023
A phase II single-arm, multicenter, open-label neoadjuvant study of pembrolizumab in combination with nab-paclitaxel followed by pembrolizumab in combination with epirubicin and cyclophosphamide in patients with triple-negative breast cancer: Neoimmunoboost.
Peter A Fasching ... Matthias W Beckmann
Journal of Clinical Oncology | VOL. 38
Peter A Fasching, et. al.Peter A Fasching ... Matthias W Beckmann
20 May 2020
View more papers

More From: Annals of oncology : official journal of the European Society for Medical Oncology

Paper Title
Journal
Date
Author
Efficacy of TIL Therapy in Advanced Cutaneous Melanoma in the Current Immuno-oncology Era: Updated Systematic Review and Meta-analysis
S Martín-Lluesma ... G Coukos
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. -
S Martín-Lluesma, et. al.S Martín-Lluesma ... G Coukos
23 Jul 2024
Exploiting the tumor microenvironment and tumor mechanobiology for the treatment of cancer cachexia
Kostas A Papavassiliou ... Athanasios G Papavassiliou
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. -
Kostas A Papavassiliou, et. al.Kostas A Papavassiliou ... Athanasios G Papavassiliou
23 Jul 2024
Immune Checkpoint Inhibitors in Endometrial Cancer: A Cinderella Story
N Colombo ... M Jalving
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 35
N Colombo, et. al.N Colombo ... M Jalving
22 Jul 2024
Overall survival in first-line HR+/HER2- advanced breast cancer in the era of CDK4/6 inhibitors
Rodrigo Sánchez-Bayona ... Mafalda Oliveira
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 35
Rodrigo Sánchez-Bayona, et. al.Rodrigo Sánchez-Bayona ... Mafalda Oliveira
22 Jul 2024
View more papers